חוב לטווח ארוך: genelux.com (GNLX)

This daily price chart for Genelux Corporation (GNLX) illustrates the performance of a company whose success relies on developing innovative anti-tumor systems, patenting technologies, and forming partnerships with pharmaceutical behemoths. The business fully delegates production and testing to external contractors, maintaining no in-house facilities. Current financial health, standing at 0.00, is sustained by investments, as the testing phase precludes the existence of stable operating income.

This indicator aggregates the company's obligations with a maturity of more than one year, reflecting the overall credit burden on capital. An increase in this metric signals rising interest expenses, which directly limits net profit. For Genelux Corporation (GNLX), borrowings are critical for scaling the Olvi-Vec platform and developing the oncology ecosystem. By analyzing the time series of the company's long-term debt, an investor can identify points of extreme corporate leverage.